Latest Charles River Laboratories International (NYSE:CRL) News

Charles River Laboratories delivered a second consecutive quarter of organic revenue growth and raised its 2026 outlook, despite reported revenue falling after divestitures. The quarter’s sharp GAAP earnings increase was heavily amplified by a US$245.6 million tax reserve reversal.